Scher HI - Search Results

1

Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase III trials.

Fizazi K, Flaig TW, Stöckle M, Scher HI, de Bono JS, Rathkopf DE, Ryan CJ, Kheoh T, Li J, Todd MB, Griffin TW, Molina A, Ohlmann CH. Fizazi K, et al. Among authors: scher hi. Ann Oncol. 2016 Apr;27(4):699-705. doi: 10.1093/annonc/mdv545. Epub 2015 Nov 25. Ann Oncol. 2016. PMID: 26609008 Free PMC article. Clinical Trial.

2

A phase II trial of interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma.

Ilson DH, Motzer RJ, Kradin RL, Vogelzang NJ, Bajorin DF, Scher HI, Nanus D, O'Moore P, Marathias K, Bosl GJ. Ilson DH, et al. Among authors: scher hi. J Clin Oncol. 1992 Jul;10(7):1124-30. doi: 10.1200/JCO.1992.10.7.1124. J Clin Oncol. 1992. PMID: 1607918 Clinical Trial.

3

Trimetrexate in prostatic cancer: preliminary observations on the use of prostate-specific antigen and acid phosphatase as a marker in measurable hormone-refractory disease.

Scher HI, Curley T, Geller N, Engstrom C, Dershaw DD, Lin SY, Fitzpatrick K, Nisselbaum J, Schwartz M, Bezirdjian L, et al. Scher HI, et al. J Clin Oncol. 1990 Nov;8(11):1830-8. doi: 10.1200/JCO.1990.8.11.1830. J Clin Oncol. 1990. PMID: 1700078

4

Predicting biologic potential in prostate cancer.

Scher HI. Scher HI. Curr Opin Oncol. 1990 Jun;2(3):520-8. Curr Opin Oncol. 1990. PMID: 2092769 Review. No abstract available.

5

A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors.

Bosl GJ, Geller NL, Bajorin D, Leitner SP, Yagoda A, Golbey RB, Scher H, Vogelzang NJ, Auman J, Carey R, et al. Bosl GJ, et al. J Clin Oncol. 1988 Aug;6(8):1231-8. doi: 10.1200/JCO.1988.6.8.1231. J Clin Oncol. 1988. PMID: 2457657 Clinical Trial.

6

Should single agents be standard therapy for urothelial tract tumors?

Scher HI. Scher HI. J Clin Oncol. 1989 Jun;7(6):694-7. doi: 10.1200/JCO.1989.7.6.694. J Clin Oncol. 1989. PMID: 2715800 No abstract available.

7

Detection of circulating tumor cells in patients with localized and metastatic prostatic carcinoma: clinical implications.

Ghossein RA, Scher HI, Gerald WL, Kelly WK, Curley T, Amsterdam A, Zhang ZF, Rosai J. Ghossein RA, et al. Among authors: scher hi. J Clin Oncol. 1995 May;13(5):1195-200. doi: 10.1200/JCO.1995.13.5.1195. J Clin Oncol. 1995. PMID: 7537803

8

Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer.

Kelly WK, Curley T, Leibretz C, Dnistrian A, Schwartz M, Scher HI. Kelly WK, et al. Among authors: scher hi. J Clin Oncol. 1995 Sep;13(9):2208-13. doi: 10.1200/JCO.1995.13.9.2208. J Clin Oncol. 1995. PMID: 7545218 Clinical Trial.

9

Suramin and hydrocortisone: determining drug efficacy in androgen-independent prostate cancer.

Kelly WK, Scher HI, Mazumdar M, Pfister D, Curley T, Leibertz C, Cohen L, Vlamis V, Dnistrian A, Schwartz M. Kelly WK, et al. Among authors: scher hi. J Clin Oncol. 1995 Sep;13(9):2214-22. doi: 10.1200/JCO.1995.13.9.2214. J Clin Oncol. 1995. PMID: 7666079 Clinical Trial.

10

Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer.

Seidman AD, Scher HI, Gabrilove JL, Bajorin DF, Motzer RJ, O'Dell M, Curley T, Dershaw DD, Quinlivan S, Tao Y, et al. Seidman AD, et al. Among authors: scher hi. J Clin Oncol. 1993 Mar;11(3):408-14. doi: 10.1200/JCO.1993.11.3.408. J Clin Oncol. 1993. PMID: 7680373 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

684 results

Search Page